A. Jager

Borstkanker Onderzoek Groep

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

6 more share only the name and are not shown

Trial papers

PubMed author-name match

Trials

Studies that name A. Jager as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:27 UTC. Open this list on ClinicalTrials.gov

Ph3
NCT03425838 · Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
Borstkanker Onderzoek Groep · active not recruiting · Breast Neoplasm Female · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 22:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 6 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:27 UTC. The ranking covers the 200 most relevant of 62 PubMed records, and a shared surname and initials can bring in a namesake. All 62 on PubMed

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Ann Oncol · 2022
399 citations
RCR 26.2
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Ann Oncol · 2018
168 citations
RCR 5.3
Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.
Ann Neurol · 2002
100 citations
RCR 2.6
A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz(®) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED(®) lamp.
Br J Dermatol · 2016
87 citations
RCR 4.9
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.
Nature · 2024
82 citations
RCR 8.2
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Gynecol Oncol · 2019
64 citations
RCR 2.2
Relevance of arm position and muscle activity on three-dimensional glenohumeral translation in patients with traumatic and atraumatic shoulder instability.
Am J Sports Med · 2002
63 citations
RCR 3.3
Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
BMC Cancer · 2018
56 citations
RCR 1.6
Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients.
Ann Oncol · 2015
46 citations
RCR 1.3
The effect of timing of orthodontic therapy on the outcomes of regenerative periodontal surgery in patients with stage IV periodontitis: A multicenter randomized trial.
J Clin Periodontol · 2021
43 citations
RCR 5.1